ReviewCell death & disease2025
Targeting tumour-infiltrating B cells: mechanisms and advances in cancer therapy.
Review in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance.Antibodies (Basel, Switzerland) · 2026Review
- B Cells are Activated via a Nanoporous Interface that Stabilizes Microvilli and Engages Mechanosensitive Ion Channels.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Construction of a risk model based on folate metabolism-related genes to predict prognosis and immunological characteristics of stomach adenocarcinoma.Discover oncology · 2026Article
- Regulatory B-cell states in NSCLC immunotherapy resistance: mechanisms, spatial context and translational implications.Cancer immunology, immunotherapy : CII · 2026Review
- Exploring multiple biomarkers and constructing ferroptosis-associated competing endogenous RNA networks as dual targets in retinoblastoma.Oncology letters · 2026Article
- Review
- B-cells in breast cancer: current insights and challenges.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of immunotherapy has heralded a new era in cancer treatment, with countless patients reaping the benefits of this innovative approach. While the majority of immunotherapy research has concentrated on T cells, there is a growing body of evidence highlighting the significant role of tumor-infiltrating B cells(TIL-Bs) in tumor immunity. This review synthesizes the potential mechanisms by which B cells contribute to tumor proliferation, metastasis, drug resistance, and angiogenesis. We provide a comprehensive analysis of the role of TIL-Bs within the tumor microenvironment(TME) and their impact on the cancer immune response, emphasizing their dual role as both allies and adversaries in the fight against cancer. To explain this phenomenon, we propose a dynamic regulatory framework of the TME targeting B cells, which indicates that the functions of B cells adjust in response to the dynamic changes of the tumor microenvironment. Understanding the mechanisms of B cell action within the TME is crucial for the development of targeted immunotherapies that leverage TIL-Bs. Finally, this article summarizes the latest advances in TIL-Bs in cancer immunotherapy and provides a historical overview of the evolution of immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.